Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AEE788 · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| AEE788 + non EIACD | EXPERIMENTAL | - |
| AEE788 + EIACD | EXPERIMENTAL | - |
| AEE788 200 mg + RAD001 5 mg | EXPERIMENTAL | AEE788 200 mg qd, RAD001 5 mg qd |
| AEE788 150 mg + RAD001 5mg | EXPERIMENTAL | AEE788 150 mg qd, RAD001 5 mg qod |
| 1 | EXPERIMENTAL | Continuous daily dosing |
| 2 | EXPERIMENTAL | Monday, Wednesday, Friday Dosing |
| Name | Type | Description |
|---|---|---|
| AEE788 | DRUG | - |
| everolimus | DRUG | Everolimus was formulated as tablets of 2.5 mg and 5 mg strength and supplied in blister packs. |
Inclusion Criteria: * Histologically confirmed GBM in first or second recurrence or relapse * Adequate hematologic, hepatic and renal function * Age ≥ 18 years * Karnofsky performance status score ≥ 70% * Life expectancy ≥ 12 weeks Exclusion Criteria: * Peripheral neuropathy \> grade 1 * Diarrhea...
AEE788 is an investigational oral small molecule developed by Novartis AG (ticker NVS) for the treatment of cancer. It has been studied in adults with advanced solid tumors and in patients with glioblastoma multiforme and other brain and central nervous system tumors. It remains in Phase 1 clinical development.
AEE788 is an inhibitor of EGFR, ERBB2, FLT1 and KDR. By inhibiting these receptor tyrosine kinases, it is designed to interfere with signaling pathways involved in tumor cell growth and blood vessel formation. It is a small molecule administered orally.
AEE788 is developed by Novartis AG, which trades under the ticker NVS. Novartis sponsored the Phase 1 clinical trials of AEE788 conducted in the United States in adults with advanced cancer and glioblastoma multiforme.
AEE788 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. All three recorded trials of AEE788 are Phase 1 studies and all have completed, with no active trials currently listed.
AEE788 has been evaluated in three completed Phase 1 trials: NCT00118456 in adults with advanced cancer, NCT00116376 in patients with recurrent or relapsed glioblastoma multiforme, and NCT00107237 combining AEE788 with everolimus in recurrent or relapsed glioblastoma multiforme. All were conducted in the United States.
AEE788 has been studied in Phase 1 trials as a treatment for recurrent or relapsed glioblastoma multiforme, including one study combining it with everolimus. These trials enrolled adults aged 18 years and older. AEE788 is investigational and is not an approved therapy for glioblastoma multiforme.